The role of pharmacogenomics in metastatic renal cell carcinoma
作者: Daniel CastellanoJuan Antonio VirizuelaJosefina CruzJuan Manuel SepulvedaMaribel SáenzLuís Paz-Ares
作者单位: 1Hospital Universitario 12 de Octubre
2Hospital Universitario Virgen de la Macarena
3Hospital Nuestra Señora de la Candelaria
4Hospital Universitario Virgen de la Victoria
5Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío
刊名: Cancer and Metastasis Reviews, 2012, Vol.31 (1), pp.29-32
来源数据库: Springer Nature Journal
DOI: 10.1007/s10555-012-9356-x
关键词: Single nucleotide polymorphismsPharmacokineticPharmacodynamicBiomarkers
英文摘要: Abstract(#br)Pharmacogenomics is the study of how variation in the genetic background affects an individual’s response to a specific drug and/or its metabolism. Using knowledge about the genes which produce the enzymes that metabolize a specific drug, a physician may decide to raise or lower the dose, or even change to a different drug. Targeted therapy with tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors has led to a substantial improvement in the standard of care for patients with advanced or metastatic renal cell carcinoma (RCC). Although few studies have identified biomarkers that predict the response of targeted drugs in the treatment of metastatic RCC, some associations have been found. Several studies have identified genetic polymorphisms with...
全文获取路径: Springer Nature  (合作)
影响因子:7.787 (2012)

  • carcinoma 癌症
  • metastatic 新陈代谢的
  • renal 肾的